Unlisted holdings
Data as at : 01/12/2023
% of total assets |
---|
4.8 |
Please note that the percentage of unlisted holdings is displayed for companies that have reported this data to the AIC. “N/R” means the data has not been reported to the AIC. Where data is reported, it may be subject to valuation lags.
Top holdings
Data as at : 31/12/2023
Investment | % of total assets |
---|---|
Amgen Inc | 8.8 |
Biogen Inc | 8.5 |
Scholar Rock Holding Corp | 4.8 |
Biomarin Pharmaceutical Inc | 4.7 |
Ionis Pharmaceuticals Inc | 4.4 |
Vaxcyte Inc Ordinary Shares | 4.2 |
Quantumpharm Inc (Xtalpi) - Pfd | 3.7 |
Sarepta Therapeutics Inc | 3.7 |
Neurocrine Biosciences Inc | 3.3 |
Other Assets And Liabilities | -8.6 |
Geographic breakdown
Data as at : 31/03/2024
Country | % of total assets |
---|---|
USA | 84.5 |
Netherlands | 4.7 |
China | 2.9 |
Canada | 1.3 |
Depending on the nature of the underlying asset classes, geographic breakdowns may not always add up to 100%.
Industry breakdown
Data as at : 31/03/2024
Industry | % of total assets |
---|---|
Healthcare | 105.0 |
Preferred | 3.2 |
Cash Equivalents | 0.6 |
Asset breakdown
Data as at : 31/03/2024
Asset | % of total assets |
---|---|
Stock | 108.9 |
Other | -9.5 |
Cash/Cash equivalents | 0.6 |
Detailed asset breakdown
Data as at : 31/03/2024
Asset | % of total assets |
---|---|
North America - stock | 100.1 |
Asia (excl Japan) - stock | 3.4 |
Preferred stock | 3.2 |
Europe - Small-cap stock | 1.5 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.